Showing results (1-10 of 318) with videos related to
Sort By:
Pageof 32
Urology|May 16, 2006
Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?Timothy J Daskivich, William K OhCurrent Opinion in Urology|May 9, 2006
Recent progress in hormonal therapy for advanced prostate cancerTimothy J Daskivich, William K OhUrology|October 2, 2007
Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapyTimothy J Daskivich, Meredith M Regan, William K OhThe Journal of Urology|October 31, 2006
Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4Timothy J Daskivich, Meredith M Regan, William K OhEuropean Urology|August 28, 2016
Online Ratings Systems for Physicians and Institutions: Limitations of the Current State of the ArtTimothy J Daskivich, Brennan Spiegel, Hyung L KimCancer|February 23, 2008
Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effectRobert W Ross, Wanling Xie, Meredith M Regan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2016
Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After ProstatectomyZachary S Zumsteg, Timothy J Daskivich, Howard M SandlerEuropean Urology Oncology|August 15, 2019
Development and Validation of an Improved Pathological Nodal Staging System for Urothelial Carcinoma of the BladderDevin N Patel, Michael Luu, Zachary S Zumsteg, et al.The Journal of Urology|March 26, 2016
Life Expectancy and Variation in Treatment for Early Stage Kidney CancerTimothy J Daskivich, Hung-Jui Tan, Mark S Litwin, et al.JAMA Oncology|December 14, 2018
Parallels Between Low-Risk Prostate Cancer and Thyroid Cancer: A ReviewAllen S Ho, Timothy J Daskivich, Wendy L Sacks, et al.Pageof 32